


PHARMACEUTICAL 2022

Hepion Pharmaceuticals Inc. Rank 194 of 475





PHARMACEUTICAL 2022

Hepion Pharmaceuticals Inc. Rank 194 of 475

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 182% points. The greatest weakness of Hepion Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -54%, being 223% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	97,452
Cost of Goods Sold	0
Intangible Assets	1,871
Liabilities, Current	8,206
Liabilities, Non-Current	50
Other Assets	4,077
Other Compr. Net Income	0
Other Expenses	8.9
Other Liabilities	2,301
Other Net Income	-2,310
Property and Equipment	153
Research and Development	20,395
Revenues	0
Selling, General and Administrative Expense	10,008

Output Variable	Value in 1000 USD
Assets	103,552
Liabilities	10,557
Expenses	30,412
Stockholders Equity	92,995
Net Income	-32,722
Comprehensive Net Income	-32,722
Economic Capital Ratio	-54%